Vaxcyte (PCVX) Shares Outstanding (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Shares Outstanding (Entity) of $144.3 million for Q1 2026, up 11.92% year-over-year from $128.9 million in Q1 2025, and up 10.11% quarter-over-quarter from $131.1 million in Q4 2025.
Vaxcyte (PCVX) Shares Outstanding (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Shares Outstanding (Entity) for 8 consecutive years, with $144.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 11.92% year-over-year to $144.3 million; the TTM figure through Mar 2026 stood at $144.3 million (up 11.92% YoY), while the FY2025 annual figure was $131.1 million, up 4.94% from the prior year.
- Shares Outstanding (Entity) rose to $144.3 million in Q1 2026 per PCVX's latest filing, from $131.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $144.3 million in Q1 2026 and bottomed at $56.5 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $102.3 million across 5 years, with a median of $108.8 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 60.02% — and 2025, when it grew 4.5%.
- Vaxcyte's Shares Outstanding (Entity) stood at $64.9 million in 2022, then surged by 46.99% to $95.4 million in 2023, then jumped by 30.96% to $124.9 million in 2024, then gained by 4.94% to $131.1 million in 2025, then grew by 10.11% to $144.3 million in 2026.
- Business Quant data shows PCVX's Shares Outstanding (Entity) at $144.3 million in Q1 2026, $131.1 million in Q4 2025, and $130.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 144.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.49 Mn |
| Mar 31, 2026 | 139.51 Mn |
| Dec 31, 2025 | 136.09 Mn |
| Sep 30, 2025 | 136.20 Mn |
| Jun 30, 2025 | 136.03 Mn |
| Mar 31, 2025 | 135.69 Mn |
| Dec 31, 2024 | 122.00 Mn |
| Sep 30, 2024 | 123.69 Mn |
| Jun 30, 2024 | 117.26 Mn |
| Mar 31, 2024 | 111.69 Mn |
| Dec 31, 2023 | 97.16 Mn |
| Sep 30, 2023 | 101.67 Mn |
| Jun 30, 2023 | 98.06 Mn |
| Mar 31, 2023 | 86.21 Mn |
| Dec 31, 2022 | 64.88 Mn |
| Sep 30, 2022 | 61.99 Mn |
| Jun 30, 2022 | 60.82 Mn |
| Mar 31, 2022 | 57.55 Mn |
| Dec 31, 2021 | 51.92 Mn |
| Sep 30, 2021 | 52.19 Mn |